Sun Pharma Denies Speculation On $12 Billion Organon Deal

Sun Pharma, India’s largest drugmaker, has issued a clarification regarding media reports linking it to a potential $12 billion acquisition of Organon. The company emphasized that the information is speculative and does not warrant any official disclosure under regulatory norms.

Market Clarification

The clarification comes after reports suggested Sun Pharma was exploring a major acquisition deal with Organon, a global pharmaceutical company. Sun Pharma has firmly denied the speculation, stating that no binding agreement or material development has taken place.

Investor Assurance

By addressing the rumors promptly, Sun Pharma aims to reassure investors and stakeholders about its compliance with disclosure requirements. The company reiterated its commitment to maintaining transparency in line with SEBI regulations and corporate governance standards.

Key Highlights

• Sun Pharma denies speculation of $12 billion Organon acquisition
• Company confirms no material event requiring disclosure
• Clarification issued to maintain investor confidence and transparency
• Commitment to SEBI compliance and corporate governance reaffirmed

Sources: Company filing, media reports on Sun Pharma clarification